DPAGT1-CDG: Functional analysis of diseasecausing pathogenic mutations and role of endoplasmic reticulum stress

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Pathogenic mutations in DPAGT1 are manifested as two possible ph...

ver descrição completa

Detalhes bibliográficos
Autores: Yuste-Checa, Patricia, Vega, Ana I., Martin-Higueras, Cristina, Medrano, Celia, Gámez Abascal, María Alejandra, Ruiz Desviat, Lourdes, Ugarte, Magdalena, Pérez-Cerdá, Celia, Pérez González, María Belén
Tipo de documento: artigo
Data de publicação:2017
País:España
Recursos:Universidad Autónoma de Madrid
Repositório:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglês
OAI Identifier:oai:repositorio.uam.es:10486/680112
Acesso em linha:http://hdl.handle.net/10486/680112
https://dx.doi.org/10.1371/journal.pone.0179456
Access Level:Acceso aberto
Palavra-chave:DPAGT1
Disease
Pathogenic mutations
Endoplasmic reticulum stress
Therapies
Biología y Biomedicina / Biología
Descrição
Resumo:This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Pathogenic mutations in DPAGT1 are manifested as two possible phenotypes: congenital disorder of glycosylation DPAGT1-CDG (also known as CDG-Ij), and limb-girdle congenital myasthenic syndrome (CMS) with tubular aggregates. UDP-N-acetylglucosamine-dolichylphosphate N-acetylglucosamine phosphotransferase (GPT), the protein encoded by DPAGT1, is an endoplasmic reticulum (ER)-resident protein involved in an initial step in the N-glycosylation pathway. The aim of the present study was to examine the effect of six variants in DPAGT1 detected in patients with DPAGT1-CDG, and the role of endoplasmic reticulum stress, as part of the search for therapeutic strategies to use against DPAGT1-CDG. The effect of the six mutations, i.e., c.358C > A (p.Leu120Met), c.791T > G (p.Val264Gly), c.901C > T (p.Arg301Cys), c.902G > A (p.Arg301His), c.1154T > G (p.Leu385Arg), and of the novel mutation c.329T > C (p.Phe110Ser), were examined via the analysis of DPAGT1 transcriptional profiles and GTP levels in patient-derived fibroblasts. In addition, the transient expression of different mutations was analysed in COS-7 cells. The results obtained, together with those of bioinformatic studies, revealed these mutations to affect the splicing process, the stability of GTP, or the ability of this protein to correctly localise in the ER membrane. The unfolded protein response (UPR; the response to ER stress) was found not to be active in patient-derived fibroblasts, unlike that seen in cells from patients with PMM2-CDG or DPM1-CDG. Even so, the fibroblasts of patients with DPAGT1-CDG seemed to be more sensitive to the stressor tunicamycin. The present work improves our knowledge of DPAGT1-CDG and provides bases for developing tailored splicing and folding therapies